Selective modulators for the nuclear receptor Nurr1
核受体 Nurr1 的选择性调节剂
基本信息
- 批准号:9975246
- 负责人:
- 金额:$ 35.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AgonistAmodiaquineAntimalarialsAromatic Amino AcidsBindingBinding SitesBiological AssayBiologyBiophysicsBrain-Derived Neurotrophic FactorCellsCellular AssayChemicalsComplexCrystallizationCysteineDNA Binding DomainDNA SequenceDataDevelopmentDiseaseDisease ProgressionDisulfidesDopamineFDA approvedFoundationsFoxesGDNF receptorsGene ExpressionGenesGenetic TranscriptionHomeostasisHumanHuman DevelopmentIn VitroIndividualLearningLegal patentLigand BindingLigand Binding DomainLigandsLiteratureMaintenanceMidbrain structureMolecular ConformationNeurodegenerative DisordersNuclear ReceptorsNurr1 nuclear receptorOrphanOxidative StressParkinson DiseasePharmaceutical PreparationsPharmacologyPhysiologicalPlayPolymersProteinsPublishingRXRRXRA geneReactionRegulationReportingResearchRoentgen RaysRoleSideSignal TransductionStructureSymptomsTechnologyTherapeuticWorkX-Ray CrystallographyZebrafishadductanalogdimerdopaminergic neurondrug developmentgene synthesisin vivomonomermotor deficitnervous system disorderprogramsreceptorreuptakescaffoldscreeningsmall moleculetherapeutic targettooltranscription factor
项目摘要
PROJECT SUMMARY
Nuclear receptors are a superfamily of ligand-regulated transcription factors that play fundamental roles in
human development, homeostasis, and disease. These receptors interact with small molecules, protein
partners, and DNA sequences to regulate the transcription of specific target genes. Developing ligands that
stabilize specific conformational states of the receptor, and thus drive the transcription of specific target genes,
is a prerequisite for developing effective nuclear receptor therapeutics.
The nuclear receptor Nurr1 (NR4A2) is widely recognized as a therapeutic target for Parkinson's disease,
potentially modifying both the symptoms and progression of the disease. Current therapeutics for Parkinson's
disease are symptom-modifying only and lose efficacy as the disease progresses. Although “Nurr1 agonists”
have been reported in both the scientific and patent literature, there is little evidence these ligands directly
activate the receptor. The only published crystal structure of Nurr1 reveals two distinctive features that have
hindered progress developing small molecules targeting this receptor: Nurr1 lacks both the canonical nuclear
receptor ligand binding pocket and the classical binding site for protein partners.
Using an orthogonal drug development strategy called disulfide-trapping, we identified ~50 small molecules
that bind directly to Nurr1 and form covalent adducts with a native cysteine residue in the ligand binding
domain. We also identified an endogenous ligand that forms a reversible covalent adduct with the same
cysteine residue. Co-crystal structures for three of these ligand-receptor complexes show Nurr1 in three
distinctly different conformations. The proposed research will capitalize on these findings to develop chemical
probes for Nurr1 that can be used to unravel the receptor's complex biology. Successful completion of these
aims will define the relationships between individual ligand scaffolds, Nurr1 conformational states, and specific
Nurr1 target genes, thereby providing the foundation for rationally developing new PD therapeutics.
In Aim 1, we will generate covalent ligands for Nurr1, suitable for cellular assays, and use them to identify the
target genes associated with different conformational states of the receptor.
In Aim 2, we will identify functional analogs of the endogenous Nurr1 ligand that will enable cellular studies
probing the receptor's regulation.
In Aim 3, we will identify ligands that stabilize additional conformations of the receptor (e.g. heterodimer with
RXR) and solve co-crystal structures of the resulting Nurr1 complexes.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pamela Michael England其他文献
Pamela Michael England的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pamela Michael England', 18)}}的其他基金
Selective modulators for the nuclear receptor Nurr1
核受体 Nurr1 的选择性调节剂
- 批准号:
10452585 - 财政年份:2018
- 资助金额:
$ 35.33万 - 项目类别:
Selective modulators for the nuclear receptor Nurr1
核受体 Nurr1 的选择性调节剂
- 批准号:
10207800 - 财政年份:2018
- 资助金额:
$ 35.33万 - 项目类别:
Selectively Targeting Opioid Receptor Heterodimers
选择性靶向阿片受体异二聚体
- 批准号:
8225136 - 财政年份:2011
- 资助金额:
$ 35.33万 - 项目类别:
Selectively Targeting Opioid Receptor Heterodimers
选择性靶向阿片受体异二聚体
- 批准号:
8133623 - 财政年份:2011
- 资助金额:
$ 35.33万 - 项目类别:
SYNTHESIS OF CONSTITUTIVELY ACTIVE SEROTONIN RECEPTORS
组成型活性血清素受体的合成
- 批准号:
2591718 - 财政年份:1997
- 资助金额:
$ 35.33万 - 项目类别:
SYNTHESIS OF CONSTITUTIVELY ACTIVE SEROTONIN RECEPTORS
组成型活性血清素受体的合成
- 批准号:
2262034 - 财政年份:1996
- 资助金额:
$ 35.33万 - 项目类别:
相似海外基金
Antiviral activity of amodiaquine derivatives against SFTSV
阿莫地喹衍生物对SFTSV的抗病毒活性
- 批准号:
17H04084 - 财政年份:2017
- 资助金额:
$ 35.33万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of amodiaquine and its analogs as reactivators of organophosphate-inh
作为有机磷-inh再激活剂的阿莫地喹及其类似物的开发
- 批准号:
8416866 - 财政年份:2012
- 资助金额:
$ 35.33万 - 项目类别:
Development of amodiaquine and its analogs as reactivators of organophosphate-inh
作为有机磷-inh再激活剂的阿莫地喹及其类似物的开发
- 批准号:
8551780 - 财政年份:2012
- 资助金额:
$ 35.33万 - 项目类别: